Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Dec-23
- 19-Sep-24
- 17-Oct-24
- 14-Nov-24
- 21-Nov-24
Select bar for recommendation details.
Recommendations | 21-Nov-24 | |
---|---|---|
Buy | 8 | |
Outperform | 7 | |
Hold | 7 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 20 analysts offering 12 month price targets for Apellis Pharmaceuticals Inc have a median target of 46.00, with a high estimate of 78.00 and a low estimate of 20.00. The median estimate represents a 65.77% increase from the last price of 27.75.
High | 181.1% | 78.00 |
Med | 65.8% | 46.00 |
Low | -27.9% | 20.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate | +13.69% |
Average growth rate | -7.05% |
More ▼
Revenue history & estimates in USD
Average growth rate | +16.19% |
Average growth rate | +121.90% |
More ▼